Enovis earnings jump and fresh buyback plan grab investor attention
Enovis (ENOV) just posted third quarter 2026 results that moved from a heavy loss to a small profit, paired with a newly authorized US$200 million share repurchase program.
The medical technology company reported third quarter sales of US$558.73 million, compared with US$548.91 million a year earlier. Net income came in at US$3.14 million, after a net loss of US$571.15 million in the prior year period.
Basic and diluted earnings per share from continuing operations were both US$0.02, compared with a basic and diluted loss per share of US$9.99 a year ago. On a total basis, basic and diluted earnings per share were US$0.06, versus a basic and diluted loss per share of US$9.99 in the same quarter last year.
For the first nine months of 2026, Enovis reported sales of US$1,730.66 million, compared with US$1,672.29 million in the prior year. The business recorded a net loss of US$6.82 million for the period, compared with a net loss of US$663.85 million a year earlier.
Basic and diluted loss per share from continuing operations over the nine months was US$0.16, versus US$11.64 in the prior year. On a total basis, basic and diluted loss per share was US$0.12, compared with US$11.64 a year ago.
Enovis shares have reacted sharply to the earnings swing and fresh US$200 million repurchase authorization, with a 1-day share price return of 17.2%, a 7-day move of 25.47% and a 30-day gain of 57.25%. However, the 3-year total shareholder return has declined 39.52% and the 5-year total shareholder return is down 67.41%, which signals strong short term momentum but a still challenging longer term picture for holders.
Scan how Enovis compares with other health specialists showing strong balance sheets and fundamentals by jumping into our curated list of solid balance sheet and fundamentals (24 results) today.
After a 57% jump in a month and the announcement of a new US$200 million buyback plan, Enovis now sits in a very different spot for would-be buyers. Does the balance of risk and reward still tilt in their favour from here?
Most Popular Narrative: 25% Undervalued
Enovis closed at $28.62, while the most followed valuation narrative pegs fair value nearer to $38.33. This implies a material gap that current buyers and long term holders need to reconcile with the recent price spike and new buyback plan.
Enovis's focus on launching next-generation, enabling technologies such as Arvis (augmented reality navigation) and ongoing pipeline innovation in hips, knees, and shoulders positions the business to capture premium pricing, gain market share, and expand adjusted EBITDA margins as global healthcare expenditure prioritizes surgical innovation and mobility outcomes.
See why 4 investors see Enovis as 25% undervalued.
Result: Fair Value of $38.33 (UNDERVALUED)
Still, the Enovis story can break if integration of past acquisitions drags on profitability or if robotics related costs put greater pressure on free cash flow.
Find out about the key risks to this Enovis narrative.
Next Steps
Plenty of enthusiasm runs through the Enovis story, alongside clear questions about risk. Act quickly, review the underlying data for yourself, and then weigh the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Enovis?
If Enovis has sharpened your interest, do not stop here. Broaden your watchlist with a few focused searches that can surface very different opportunities.
- Target resilient balance sheets and cleaner fundamentals by scanning a list of solid balance sheet and fundamentals (24 results) that filters for financial strength and staying power.
- Zero in on value-driven opportunities by reviewing a 42 high quality undervalued stocks that highlights companies where quality and pricing may be out of sync.
- Prioritise staying power and steady progress by checking a 32 resilient stocks with low risk scores that focuses on businesses with more muted risk profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com